Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  GALA BIOP       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

RXI PHARMACTCLS : RXi Pharmaceuticals Awarded $580,000 in NIH Grants to Advance RNAi Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2011 | 03:55pm CEST

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH).

ALS Research Support. The National Institute of Neurological Disorders and Stroke (NINDS/NIH) will provide funding for an ongoing collaboration between RXi Pharmaceuticals and Robert Brown, MD, DPhil, Chair of the Department of Neurology at the University of Massachusetts Medical School in Worcester that is focused on the preclinical development of novel RNAi therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. The project aims to generate an optimized self-delivering RNAi compound (sd-rxRNA?) for ALS that can be moved into clinical development as well as establish an optimized sd-rxRNA platform for spinal cord delivery. RXi was awarded $304,559 for Phase I of the project and may apply for additional Phase II funding to continue its research in this area.

RNAi Chemical Optimization Project. A grant from the National Institute of General Medical Sciences (NIGMS) will provide funding for a project seeking to improve the delivery of RNAi therapeutics through medicinal chemistry. More specifically, RXi will explore further chemical optimization of its sd-rxRNA compounds to improve in vivo potency and expand bio-distribution for clinical applications. RXi was awarded $273,824 for Phase I of the project and may apply for additional Phase II funding to continue its research in this area.

"We are pleased to have received support for our innovative research programs that could have a significant impact on our progress lead to powerful new approaches to therapy," said Anastasia Khvorova, Ph.D. Chief Scientific Officer of RXi Pharmaceuticals. "The funding of these grants reflects the strength of our scientific team, demonstrated progress, and our determination to successfully meet the delivery challenge of RNAi therapeutics with our unique sd-rxRNA technology."

The projects described are supported by Award Number R43GM096548 from the National Institute of General Medical Sciences and Award Number R43NS074671 from the National Institute of Neurological Disorders And Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of General Medical Sciences, the National Institute Of Neurological Disorders and Stroke or the National Institutes of Health.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies. Based on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109 which targets CTGF (connective tissue growth factor), is scheduled to commence human clinical trials in anti-scarring in early 2012. RXi recently accelerated its product development focus with the acquisition of NeuVax? which is slated to commence Phase III clinical trials in low-to-intermediate HER2+ breast cancer patients, not eligible for Herceptin®, in the first half of 2012. For more information please visit us at www.rxipharma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the future expectations, plans and prospects of the development of RXi Pharmaceuticals Corporation's products. These forward-looking statements about future expectations, plans and prospects of the development of the Company's products are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

RXi Pharmaceuticals
Tamara McGrillen, 508-929-3615
ir@rxipharma.com
or
Investors
S. A. Noonan Communications
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GALA BIOP
01:06p Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data..
09/28 GALENA BIOPHARMA : Presents GALE-301 Folate Binding Protein Expression Data at t..
09/27 Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at ..
09/20 Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Eu..
09/16 GALENA BIOPHARMA : Presents Preclinical NeuVax (nelipepimut-S) Data in Ovarian a..
09/14 Galena Biopharma to Present at the 2016 Aegis Growth Conference
09/13 Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in O..
09/12 Galena Biopharma Expands GALE-401 Intellectual Property Protection with Paten..
09/09 Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Invest..
09/08 GALENA BIOPHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
More news
Sector news : Pharmaceuticals - NEC
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ($)
Sales 2016 -
EBIT 2016 -34,7 M
Net income 2016 -24,3 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0
Capi. / Sales 2017 0
Capitalization 74,4 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 1,13 $
Spread / Average Target 227%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark W. Schwartz President, Chief Executive Officer & Director
Sanford J. Hillsberg Chairman
Gavin S. Choy Senior VP-Clinical Sciences & Operations
Bijan Nejadnik Chief Medical Officer & Executive Vice President
Stephen S. Galliker Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GALA BIOP74
JOHNSON & JOHNSON16.23%326 636
ROCHE HOLDING LTD.-12.41%217 190
NOVARTIS AG-10.14%212 589
PFIZER INC.5.30%206 172
MERCK & CO., INC.19.84%175 038
More Results